Psychosis is the term used when patients experience hallucinations and delusions. Hallucinations are more likely to occur in the later stages of Parkinson’s disease, but younger and newly diagnosed patients may also experience them. Delusions are less common and only affect around 8 percent of people living with the diseases. According…

Horizon Discovery, in a collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has developed two new genetic rat models that may help scientists better understand alpha-synuclein‘s role in brain function and in the development of Parkinson’s disease (PD). Alpha-synuclein is the main molecular component of…

Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and…

AC Immune is receiving additional funding from the Michael J. Fox Foundation for Parkinson’s Research to continue developing positron emission tomography (PET) tracers for alpha-synuclein, a protein linked to Parkinson’s disease. The idea behind the project is to use alpha-synuclein as a biomarker of Parkinson’s. The PET tracers will help…

Recent research shows that the Parkinson’s disease (PD) protein, alpha-synuclein, blocks pro-survival signals from an important brain growth factor. These findings provide new reasons why neurons degenerate and are lost in patients with PD. The finding, “TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic celldeath in Parkinson’s…

Scientists have linked the clumping of alpha-synuclein protein to Parkinson’s disease, and a study in mice indicates that the clumps accumulate and spread by interacting with the protein responsible for mad cow disease. What scientists call the cellular prion protein, or PrPc, is associated with the development of a number…

Sumitomo Dainippon Pharma has asked Japanese authorities to approve its Trerief (zonisamide) as a new therapy for parkinsonism in dementia patients with Lewy bodies, the company announced in a press release. Trerief went on sale in Japan in March 2009 as a treatment for Parkinson’s patients who saw insufficient…

In an unexpected finding, researchers demonstrated that certain asthma drugs might protect from developing Parkinson’s disease by lowering the production of the disease-linked protein alpha-synuclein. But researchers caution against attempting to medicate with such drugs before clinical trials establish they are safe in this patient group, and that they really…

AstraZeneca has partnered with Takeda Pharmaceutical to develop and commercialize the alpha-synuclein antibody MEDI1341 for the treatment of Parkinson’s disease. MEDI1341 is expected to enter a Phase 1 clinical trial later this year. Under the terms of the agreement, AstraZeneca will supervise…

Researchers at the University of Pennsylvania developed a strategy using fluorescence that allows them to track alpha-synuclein protein and follow its path inside neurons. This is important because while scientists know that alpha-synuclein protein is involved in neurodegenerative diseases like Parkinson’s, they aren’t exactly certain how the process functions. These new…